Puma Biotechnology (PBYI) Cash & Equivalents (2011 - 2026)

Puma Biotechnology (PBYI) has 16 years of Cash & Equivalents data on file, last reported at $36.2 million in Q1 2026.

• Quarterly Cash & Equivalents fell 42.58% year-over-year to $36.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $36.2 million (down 42.58% YoY) and the FY2025 annual result came in at $29.6 million, down 57.19% from the prior year.
• Cash & Equivalents grew to $36.2 million in Q1 2026, from $29.6 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $84.6 million in Q4 2023 to a low of $29.6 million in Q4 2025.
• A 5-year average of $63.3 million and a median of $63.9 million in 2022 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2024 — Cash & Equivalents advanced 25.01% — and 2025, when it tumbled 57.19%.
• Tracing PBYI's Cash & Equivalents over 5 years: stood at $76.2 million in 2022, then climbed by 11.0% to $84.6 million in 2023, then slipped by 18.17% to $69.2 million in 2024, then plunged by 57.19% to $29.6 million in 2025, then advanced by 22.13% to $36.2 million in 2026.
• The last three Cash & Equivalents figures came in at $36.2 million (Q1 2026), $29.6 million (Q4 2025), and $53.5 million (Q3 2025), per Business Quant data.